Measuring how tumors respond to cisplatin treatment using advanced imaging and blood tests.
Quantification of cisplatin sensitivity and resistance using metabolic imaging and circulating tumor cell (CTC) biomarkers
This study is looking at how head and neck tumors react to cisplatin, a common chemotherapy drug, to help doctors understand which patients might respond well to the treatment and which might not, using advanced imaging and blood tests to make the process as easy and accurate as possible.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10917411 on NIH RePORTER |
What this research studies
This research investigates how tumors, particularly in head and neck cancers, respond to cisplatin, a common chemotherapy drug. It aims to identify predictors of treatment success or resistance by using advanced imaging techniques and analyzing circulating tumor cells in the blood. Patients undergoing cisplatin therapy will be monitored for changes in tumor metabolism and other biological markers, which may help tailor more effective treatment plans. The study focuses on minimizing invasiveness while maximizing the accuracy of response assessment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with head and neck squamous cell carcinoma who are scheduled to receive cisplatin as part of their treatment.
Not a fit: Patients with tumors that are not responsive to cisplatin or those who are not receiving this chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better predictions of treatment outcomes for patients receiving cisplatin, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results using similar imaging and biomarker approaches to assess tumor response to chemotherapy.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Lai, Stephen Y — University of Tx Md Anderson Can Ctr
- Study coordinator: Lai, Stephen Y
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.